etherna
etherna.be
Actively hiring
Health Care
Vaccines
Biotechnology
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Grants
$11.6M
3 grants · CORDIS
Backers
1
Fund+
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 1, 2021
Won a grant $5.5M · CORDIS
Sep 1, 2019
Won a grant $5.9M · CORDIS
Jan 1, 2017
Won a grant $232k · CORDIS
2017
Founded
Funding rounds
Backed byfrom the funds' portfolios and accelerator catalogs
Fund+ Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Hone Bio develops NanoPilot, a dual-targeting technology that enables cell-specific LNP delivery whilst actively blocking off-target…
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable…
Inside Therapeutics is a company specialized in providing system for nanoparticle synthesis or nanoparticle manufacturing using…
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Gamgee is developing personalised mRNA vaccines as a cancer treatment for dogs, built from each dog’s tumour. See how it works with vets…
微滔生物成立于2025年6月25日，其前身系沙砾集团为自主研发的体内CAR-T平台独立运营而成。微滔生物将基于T 靶向 LNP 递送系统开发in vivo CAR-T管线，专注于非病毒体内靶向细胞治疗业务，该业务主要用于血液瘤及自身免疫疾病治疗。.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston
United States
HQ
Contact us
50-200 est. staff
20 Park Plaza, Suite 495, Boston, MA 02116, United States